18 July 2023— As Johnson & Johnson’s (J&J) 20-year major patent on the important, lifesaving drug-resistant tuberculosis (DR-TB) drug bedaquiline expires within the majority of nations, together with India, Doctors Without Borders / Médecins Sans Frontières (MSF) reiterated its name for the US pharmaceutical company to publicly announce it won’t implement any ‘secondary’ patents for the drug in any nation with a excessive burden of TB, and withdraw and abandon all pending secondary patent purposes for this important drug in all places.
Doctors Without Borders additionally known as for a dedication from J&J not to take any authorized motion towards any generic producer that exports generic variations of bedaquiline to or from TB high-burden nations the place secondary patents on the drug exist. The company ought to make this announcement public by the September UN TB Summit in New York.
J&J holds secondary patents in at the very least 34 of the 49 nations with a excessive burden of TB, TB-HIV and/or DR-TB, for which bedaquiline is a vital a part of therapy regimens. The Philippines is certainly one of these 34 nations (see diagram, hooked up).
Bedaquiline tablets at the moment are the spine of TB therapy regimens, advisable by the World Health Organization (WHO) for a far-improved, shorter, better-tolerated and more-effective therapy for individuals affected by DR-TB. The present advisable therapy, containing bedaquiline, is all oral, 6 months lengthy and may obtain treatment charges as excessive as 89%. This is an unlimited enchancment over the older therapies that had to be administered for 18 months and included every day painful injections. PR
Post Views: 106